Main Speakers

Prof.dr. Adriana Maggi

University of Milan, Molecular Pharmacology Lab, Milano, Italy

Professor Maggi received her doctorate degree in 1973 in Biological Sciences from the University of Milan. Following her Doctorate, Professor Maggi carried out post-doctoral research at the University of Texas Houston Medical Center, Department of Pharmacology and at Baylor College of Medicine, Department of Cell Biology. She then moved to the University of Milan as Assistant Professor. Professor Maggi is currently Professor of Pharmacology and Biotechnology and Director of the Center of Excellence on Neurodegenerative diseases of the University of Milan. Her academic research for the last 20 years has been centred on the study of the mechanism of action and regulation of steroid receptors with particular emphasis of estrogen receptors.

Website Professor Maggi

Prof.dr. Kendall Nettles

Scripps Florida, Department of Cancer Biology, Florida, USA
Dr. Kendall Nettles researches small molecule ligands, and their interaction with nuclear receptors in the cell’s interior, that may be targets for hormone-driven diseases such as breast and prostate cancers.

Website Kendall Nettles lab

Dr. Arthur Oubrie

Chief Scientific Officer at Lead Pharma, Oss, The Netherlands

Arthur Oubrie, Proficient drug discovery scientist with specific expertise in various areas including structural, computational, and medicinal chemistry, molecular pharmacology, lead identification and optimization. Manager with strong analytical and strategic skills, experience with portfolio, project, and technology management as well as business development. Contributions to the discovery of many hits, leads, optimized leads and a small number of pre-clinical and clinical candidates. Co-author of >20 research papers and co-inventor of 6 patents.
Website Lead Pharma

Prof.dr. Karolien de Bosscher

Universiteit Gent, Medical Biotechnology Center, VIB-UGent, Belgium

Prof. dr. Karolien De Bosscher has a long-standing focus on nuclear receptors in the context of anti-inflammatory action mechanisms (GR, PPARs). She obtained her PhD at UGent on the molecular mechanisms of glucocorticoids in 2000, after which she went to Cancer Research UK in London with an EMBO long-term fellowship to study TGFβ-signaling pathways. From 2003 to 2010 she coordinated nuclear receptor research at the UGent LEGEST lab, supported by an FWO postdoctoral fellowship. In 2007, she won the PFIZER Prize and in 2012 she received not only the Prize of the Academy for Fundamental Research in Medicine but was also honored with the Belgian Endocrine Society Lecture Award, sponsored by NOVO NORDISK, for outstanding achievements in the field of endocrinology. She currently guides the Nuclear Receptor Signaling Unit at the UGent-VIB departments of biochemistry and medical protein research and holds a full professorship (BOF-ZAP) at the medicine faculty of UGent.

Prof.dr. Holger Reichardt

Institute for Cellular and Molecular Immunology, University Medical Center Göttingen, Germany
  • 1989-1994: Studies in Biochemistry at the Universities of Tübingen, Munich and Fribourg/Switzerland
  • 1994-1997: PhD thesis at the German Cancer Research Center and the University of Heidelberg
  • 1997-2001: Junior group leader with Günther Schütz, German Cancer Research Center Heidelberg
  • 2001-2002: Independent group leader, Institute for Virology and Immunobiology, University of Würzburg
  • 2002-2006: Professor of Molecular Immunology, University of Würzburg
  • since 2007: Professor of Experimental Immunology, University of Göttingen

Inflammatory diseases such as Multiple Sclerosis, Type I Diabetes mellitus, Asthma and Graft-versus-Host-Disease are major health problems in the western world, often require lifetime medical treatment and may result in permanent disability and early death. Generally, therapy is often unsatisfactory and accompanied by side effects. Therefore our work aims at better understanding the mechanisms underlying traditional and new treatment regimens for chronic inflammatory diseases. First and foremost our approaches concern the mode of action of glucocorticoids, which are still the mainstay of many therapies employed in the clinic. To accomplish our goal, we primarily focus on T lymphocytes and myeloid cells and use a plethora of molecular and immunological techniques, different cell culture systems and a variety of animal models. Special expertise of our group also include the use of retroviral and lentiviral vectors for RNA interference and the generation of transgenic and knockdown mice and rats. Since glucocorticoid therapy is accompanied by metabolic side effects, some approaches in the lab also deal with the impact of anti-inflammatory therapies on muscle, liver, bone and the gastrointestinal tract. All our projects are integrated in a dense network of cooperation involving colleagues from allover the world.